Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Genomic and Transcriptomic Profiling Reveals Distinct Subsets Associated with Outcomes in Mantle Cell Lymphoma

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-139955

Published: 2020

Journal Articles

Clonal Phylogeny and Evolution of Critical Cytogenetic Aberrations in Multiple Myeloma at Single Cell Level

Yuting Yan, Xiaoqi Qin, Lanting Liu, Shuhui Deng, MD, Jiahui Liu, Huishou Fan, Weiwei Sui, MD, Fu Mingwei, MD, Xue-Han Mao, MD, Zhen Yu, MD, Dehui Zou, MD, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-143447

Published: 2020

Journal Articles

Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation

Chenxing Du, MD, Xue-Han Mao, MD, Jiahui Liu, Huishou Fan, Weiwei Sui, MD, Shuhui Deng, MD, Shuhua Yi, MD, Wenyang Huang, Yan Xu, Chengwen Li, Jiawei Zhao, Dehui Zou, MD, Yaozhong Zhao, Jianxiang Wang, MD, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-140909

Published: 2020

Journal Articles

Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

Ryu Lv, Yi Wang, Tingyu Wang, Xiong Wenjie, Huijun Wang, Yuting Yan, Qi Wang, Wei Liu, Gang An, MD PhD, Wenyang Huang, Weiwei Sui, MD, Yan Xu, MD, Zhen Yu, MD, Dehui Zou, MD, Jianxiang Wang, MD, Lugui Qiu, MD, Shuhua Yi, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-138592

Published: 2020

Journal Articles

The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

Chenxing Du, MD, Yi Wang, Xue-Han Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Yan Xu, Weiwei Sui, MD, Shuhui Deng, MD, Fu Mingwei, MD, Chengwen Li, Jiawei Zhao, Shuhua Yi, MD, Dehui Zou, MD, Yaozhong Zhao, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140718

Published: 2020

Journal Articles

An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-138734

Published: 2020

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma for Long-Term Follow-up: Single Center Results

Weiwei Sui, MD, Dehui Zou, MD, Gang An, MDPhD, Shuhui Deng, MD, Yan Xu, MDPhD, Shuhua Yi, MD,PhD, Zengjun Li, MD,PhD, Yaozhong Zhao, Lugui Qiu, MD

Blood (2016) 128 (22): 5836.

https://doi.org/10.1182/blood.V128.22.5836.5836

Published: 2016

Journal Articles

Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis

Mu Hao, MD PhD, Meirong Zang, PhD, Yan Xu, MDPhD, Yu Qin, MD PhD, Lei Zhao, MD PhD, Shuhui Deng, MD PhD, Weiwei Sui, MD, Gang An, MDPhD, Zengjun Li, MD PhD, Yi Shuhua, MD PhD, Fenghuang Zhan, MD PhD, Lugui Qiu, MD PhD

Blood (2015) 126 (23): 4186.

https://doi.org/10.1182/blood.V126.23.4186.4186

Published: 2015

Journal Articles

Clonal Evolution Paths Significantly Impact the Outcome of Myeloma

Xiaoqi Qin, MD, Gang An, MDPhD, Lin-ping Hu, MD, Yu Qin, MD PhD, Yan Xu, MDPhD, Xiaoyan Feng, Meirong Zang, Shuhui Deng, MD PhD, Weiwei Sui, MD, Shuhua Yi, MD PhD, Zengjun Li, Sr., Lin-hua Yang, MD, Tao Cheng, MD, Jianxiang Wang, MD, Lugui Qiu, MD PhD

Blood (2015) 126 (23): 1784.

https://doi.org/10.1182/blood.V126.23.1784.1784

Published: 2015

Journal Articles

Voriconazole Increase the Risk of PN in Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy

Yan Xu, MDPhD, Shuhui Deng, MD, Gang An, MDPhD, Zengjun Li, Sr., Xiaoqi Qin, MD, Weiwei Sui, MD, Xiaoyan Feng, Dehui Zou, Lugui Qiu, MD PhD

Blood (2015) 126 (23): 5394.

https://doi.org/10.1182/blood.V126.23.5394.5394

Published: 2015

Journal Articles

Clonal Heterogeneityand Evolutional Paths in Multiple Myeloma Revealed By QM-FISH in Single Cell of Sequential Analysis

Xiaoqi Qin, Gang An, MD PhD, Yu Qin, PhD, Yan Xu, MD PhD, Xiaoyan Feng, MD, Meirong Zang, PhD, Weiwei Sui, MD, Shuhui Deng, MD, Shuhua Yi, Wen Zhou, PhD, Lugui Qiu, MD PhD

Blood (2014) 124 (21): 3395.

https://doi.org/10.1182/blood.V124.21.3395.3395

Published: 2014

Journal Articles

Unmeasurable Serum M-Protein Multiple Myeloma Benefit Less from Bortezomib Than Measurable Myeloma

Xiaoqi Qin, Gang An, MD PhD, Yan Xu, MD PhD, Yu Qin, PhD, Xiaoyan Feng, MD, Meirong Zang, PhD, Weiwei Sui, MD, Shuhui Deng, MD, Shuhua Yi, Wen Zhou, PhD, Lugui Qiu, MD

Blood (2014) 124 (21): 2062.

https://doi.org/10.1182/blood.V124.21.2062.2062

Published: 2014

Journal Articles

Chromosome 1q21 Gains Confer Inferior Outcomes In Multiple Myeloma Treated With Bortezomib But Copy Number Variation and Percentage Of Plasma Cells Involved Have No Additional Prognostic Value

Gang An, Yan Xu, MD., Shuhui Deng, MD., Dehui Zou, Weiwei Sui, MD., Lihui Shi, MD., Fenghuang Zhan, MD&PhD, Lugui Qiu, MD

Blood (2013) 122 (21): 1992.

https://doi.org/10.1182/blood.V122.21.1992.1992

Published: 2013

Journal Articles

Secondary Monoclonal Gammopathy Of Undetermined Significance Is Frequently Associated With High Response Rate and Superior Survival In Patients With Plasma Cell Dyscrasias

Dehui Zou, Gang An, Guoqing Zhu, Yan Xu, MD., Weiwei Sui, MD., Shuhui Deng, MD., Fenghuang Zhan, MD&PhD, Lugui Qiu, MD

Blood (2013) 122 (21): 5537.

https://doi.org/10.1182/blood.V122.21.5537.5537

Published: 2013

NARROW

Genomic and Transcriptomic Profiling Reveals Distinct Subsets Associated with Outcomes in Mantle Cell Lymphoma

Clonal Phylogeny and Evolution of Critical Cytogenetic Aberrations in Multiple Myeloma at Single Cell Level

Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation

Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma for Long-Term Follow-up: Single Center Results

Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis

Clonal Evolution Paths Significantly Impact the Outcome of Myeloma

Voriconazole Increase the Risk of PN in Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy

Clonal Heterogeneityand Evolutional Paths in Multiple Myeloma Revealed By QM-FISH in Single Cell of Sequential Analysis

Unmeasurable Serum M-Protein Multiple Myeloma Benefit Less from Bortezomib Than Measurable Myeloma

Chromosome 1q21 Gains Confer Inferior Outcomes In Multiple Myeloma Treated With Bortezomib But Copy Number Variation and Percentage Of Plasma Cells Involved Have No Additional Prognostic Value

Secondary Monoclonal Gammopathy Of Undetermined Significance Is Frequently Associated With High Response Rate and Superior Survival In Patients With Plasma Cell Dyscrasias

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only